FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia

Wednesday, September 9, 2026Salong DebbarmaView original

The FDA has granted RMAT designation to RiboX Therapeutics’ investigational treatment RXRG001 for RIX and hyposalivation.

Read the full article on the original site.